Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Rachael Flood, Colm Kirby, David Kane and Ronan Mullan, Tallaght University Hospital, Dublin, Ireland
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…
Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
zancong shen¹, Elizabeth Polvent², vijay hingorani³, Rongzi Yan⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc., San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Vanguard Healthsciences, Inc., San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
Abstract Number: 1569 • ACR Convergence 2021
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Borislav Mihov¹, Angela Stewart¹, Gregory Gamble¹, Tony Merriman², David Mount³, Lisa Stamp⁴, Ian Reid¹ and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Dunedin, New Zealand, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…
Abstract Number: 1570 • ACR Convergence 2021
AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study
Rongzi Yan¹, zancong shen², Elizabeth Polvent³, vijay hingorani⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc, Irvine, CA, ²Arthrosi Therapeutics, Inc., San Diego, CA, ³Arthrosi Therapeutics, Inc., Roseville, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882, a novel uric acid transporter 1 (URAT1) inhibitor is being developed for the treatment of gout with hyperuricemia. In Phase 1 and Phase…
Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Bilal Bengana¹, Aicha Ladjouze², Nabil Baramtane Raaf³, Chaffa Aimeur⁴, Soraya Ayoub⁵, Abdenour Boukabous⁶ and Salima Lefkir-Tafiani⁷, ¹University Hospital of Beni Messous Algiers - Rheumatology Department, Algiers, Algeria, ²Specialized hospital establishment of Benaknoune, Rheumatology, Algiers, Algeria, ³Hospital of Bitraria, Biochemistry, El Biar, Algiers, Algeria, ⁴University hospital of Mustapha Bacha, Radiology, Sidi Mhamed, Algiers, Algeria, ⁵University hospital of Beni Messous, Internal Medicine, BeniMessous, Algiers, Algeria, ⁶University Hospital of Beni Messous Algiers- Rheumatology Department, Algiers, Algeria, ⁷University Hospital of Beni Messous Algiers - Rheumatology Department, Benimessous, Algeria
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
Abstract Number: 0654 • ACR Convergence 2020
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
Matthew Belanger¹, Christina Wee¹, Kenneth Mukamal¹, Edgar Miller², Frank Sacks³, Lawrence Appel², Robert Shmerling⁴, Hyon Choi⁵ and Stephen Juraschek¹, ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Division of General Medicine, Boston, MA, ²Johns Hopkins University, School of Medicine, Department of Medicine, Division of General Internal Medicine, Baltimore, MD, ³Harvard T. H. Chan School of Public Health, Department of Nutrition, Boston, MA, ⁴Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Diet is a significant determinant of hyperuricemia and risk for gout. Dietary recommendations to prevent gout emphasize reducing purine intake; however, low-purine diets are…
Abstract Number: 1472 • ACR Convergence 2020
Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization
Natalie McCormick¹, Mark O'Connor¹, Shelby Marozoff², John Choi³, Aaron Leong¹ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, Canada, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear. Observational studies have reported positive associations…
Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Kristian Zobbe¹, Robin Christensen², Sabrina Mai Nielsen³, Lisa Stamp⁴, Marius Henriksen⁵, Anders Føhrby Overgaard⁶, Lene Dreyer⁷, Filip Krag Knop⁸, Jasvinder Singh⁹, Michael Doherty¹⁰, Pascal Richette¹¹, Arne Astrup¹², Karen Ellegaard¹, Else Marie Bartels¹³, Mikael Boesen¹⁴, Henrik Rindel Gudbergsen¹⁵, Henning Bliddal¹⁵ and Lars Erik Kristensen¹⁶, ¹The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, Denmark, ²Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Frederiksberg, Denmark, ⁴University of Otago Christchurch, Christchurch, New Zealand, ⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Copenhagen, ⁶The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Sorø, ⁷Department of Rheumatology, Aalborg UnIversity Hospital, Aalborg, Denmark, ⁸Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, Copenhagen, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Academic Rheumatology, School of Medicine, University of Nottingham, Nottingham UK, Nottingham, United Kingdom, ¹¹Department of Rheumatology, Lariboisière Hospital, Paris, France, ¹²Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark, ¹³Department of Neurology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Frederiksberg, Denmark, Copenhagen, Denmark, ¹⁴Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ¹⁵The Parker Institute - Frederiksberg og Bispebjerg Hospitaler, Frederiksberg, Denmark, ¹⁶The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…
Abstract Number: 1628 • ACR Convergence 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Simon Helfgott³, Alexander Hu⁴, Kent Kwas Huston⁵, Jordan Leonard⁶, Kelsey Milligan⁷, Scott Milligan⁷, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³BWH- HMS, Boston, MA, ⁴Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁵Kansas City Physician Partners, Kansas City, MO, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁷Trio Health, Louisville, CO, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Pegloticase is approved for severe gout in patients that are intolerant to, or whose disease is ineffectively controlled by, other uric acid lowering therapies…
Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Blanka Stiburkova¹, Yu Toyoda², Katerina Pavelcova¹, Jana Bohata¹, Pavel Ješina³, Yu Kubota², Tappei Takada² and Hiroshi Suzuki², ¹Institute of Rheumatology, Prague, Czech Republic, ²Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…
Abstract Number: 1629 • ACR Convergence 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman¹, Mona Amin², Kimmi Cox³, Simon Helfgott⁴, Alexander Hu⁵, Kent Kwas Huston⁶, Jordan Leonard⁷, Scott Milligan³, Jasvinder Singh⁸, John Tesser⁹ and Colin Edgerton¹⁰, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Arizona Arthritis & Rheumatology Associates, P.C., Scottsdale, AZ, ³Trio Health, Louisville, CO, ⁴BWH- HMS, Boston, MA, ⁵Arizona Arthritis & Rheumatology Associates, P.C., New Orleans, LA, ⁶Kansas City Physician Partners, Kansas City, MO, ⁷Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, AZ, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹⁰Articularis Healthcare, Summerville, SC
Background/Purpose: Infusion reactions and other adverse events associated with pegloticase may lead to discontinuation of treatment in patient populations that have already failed or are…
Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Megan Leask¹, Nicola Dalbeth², Lisa Stamp³, Tony Merriman⁴, Amanda Phipps-Green⁴, Ruth Topless⁴, James Boocock⁵, Hyon Choi⁶, Keresoma Leaupepe¹ and Eli Stahl⁷, ¹University of Otago, Dunedin, Otago, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago Christchurch, Christchurch, New Zealand, ⁴University of Otago, Dunedin, New Zealand, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁷Mt Sinai School of Medicine, New York, NY
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].